

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.1079US

SERIAL NO.: 09/154,334

10/033,055

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Ronald M. BURCH, et al.

FILING DATE:
September 17, 1998GROUP: 1614
1639

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
MA	AA	5	8	5	9	2	5	7	01/12/9	Talley	548	247	08/14/96
	AB	5	8	6	3	9	2	2	01/26/99	Mayer, et al.	514	270	07/02/99
	AC	5	8	4	0	7	3	1	11/24/98	Mayer, et al.	514	289	08/02/95
	AD	5	8	6	9	4	9	8	02/09/99	Mayer, et al.	514	282	07/07/97
	AE	5	8	6	1	4	1	9	01/19/99	Dube, et al.	514	334	07/11/97
	AF	5	7	8	9	4	1	3	08/04/98	Black, et al.	514	255	01/21/97
	AG	5	6	0	4	2	6	0	02/18/97	Guay, et al.	514	605	11/04/93
	AH	5	4	5	8	8	7	9	10/17/95	Singh, et al.	424	400	09/30/94
	AI	5	5	1	6	8	0	3	05/14/96	Raffa	514	570	03/01/95
MA	AJ	5	8	4	3	4	6	8	12/01/98	Burkoth, et al.	424	448	05/13/96
	AK												

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

MA	AL	Differential Inhibition of Cyclooxygenase-1 (COX-1) and -2 (COX) By NSAIDs: Consequences on Anti-Inflammatory Activity Versus Gastric and Renal Safety, M. Palret, et al., Inflammopharmacology 4: 61-70, (1996).
	AM	Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation, Derek W. Gilroy, et al. European J. Pharm 355 pp 211-217, (1998).
	AN	Cyclooxygenases 1 and 2, J.R. Vane, et al. Annu. Rev. Pharmacol. Toxicol. 38: 97-121, (1998).
	AO	Analysis of the effects of cyclooxygenase (COX)-1 and COX-2 in spinal nociceptive transmission using indomethacin, a non-selective COX inhibitor, and NS-398, a COX-2 selective inhibitor, Tatsuo Yamamoto, et al. Brain Research 739:104-110, (1996).
	AP	Comparative Analgesic Efficacy of Nimesulide and Diclofenac Gels after Topical Application on the Skin, S. Sengupta, et al., Skin Pharmacol. And Applied Skin Phys. 11: 273-278, (1998).
	AQ	Carrageenan-induced hyperalgesia is associated with increased cyclo-oxygenase-2 expression in spinal cord, Cariona Hay and Jacqueline de Belleroche, NeuroReport 8, 1249-1251, (1997).
	AR	The Mechanisms of Action of NSAIDs in Analgesia, Jeremy N. Cashman, Drugs 52 Supp. 5:13-23, (1996).
	AS	Differential effects of inhibition of isoforms of cyclooxygenase (COX-1, COX-2) in chronic inflammation, D.W. Gilroy, et al. Inflamm. Res. 47: 79-85, (1998).
MA	AT	Constitutive Cyclooxygenase (COX-1) and Inducible Cyclooxygenase (COX-2): Rationale for Selective Inhibition and Progress to Date, Don E. Griswold and Jerry L. Adams, Medicinal Research Reviews, Vol. 16, No. 2, pp. 181-206, (1996).

EXAMINER






DATE CONSIDERED

6/29/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079US		SERIAL NO.: 09/154,194 10(633,051)PTO	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Ronald M. BURCH, et al.		10/033055 10/033055 10/033055	
				FILING DATE: September 17, 1998			
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	BA	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES
	BL						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
M	BM	Cyclooxygenase in biology and disease, Raymond N. Dubois, et al., FASEB J. Vol. 12 pp. 1063-1073 (1998).					
	BN	Pharmacology of Meloxicam, A new Non-Steroidal Anti-Inflammatory Drug With An Improved Safety Profile Through Preferential Inhibition of COX-2, G. Engelhardt, British J. Rheumatology, 35 (supp 1):4-12, (1996).					
	BO	Cyclooxygenase 1 Contributes to Inflammatory Responses in Rats and Mice: Implications for Gastrointestinal Toxicity, John L. Wallace, et al. Gastroenterology, 115:101-109 (1998).					
	BP	Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications, M. Pairet and G. Engelhardt, Fundam. Clin. Pharmacol. 10:1-15, (1996).					
	BR	Involvement of Prostaglandins Produced by Cyclooxygenase-1 in Murine Visceromonociception Induced by Phenylquinone, Hidenobu Kusuvara, et al. Prostaglandins 55: 43-49, (1998).					
M	BS	Effect of COX-1 and COX-2 Inhibition on Induction and Maintenance of Carrageenan-Evoked Thermal Hyperalgesia in Rats. D. Dirig, et al. J. Pharmacol. And Experimental Therapeutics Vol285, No. 3, pp 1031-1038.					
	BT						
EXAMINER				DATE CONSIDERED 6/29/04			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079US		SERIAL NO.: 09/154,354 10/033,055	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Ronald M. BURCH, et. al.		FILING DATE: September 17, 1998	
				GROUP: 1627		1639	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	AE	9 9 0 7 4 1 3	2/18/99	WO			
	AF	9 9 3 2 1 1 9	7/1/99	WO			
	AG						
	AH						
	AI						
	AJ						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AK	Effect of meloxicam on postoperative pain after abdominal hysterectomy, J.P. Thompson et al. <i>British Journal of Anaesthesia</i> 84 (2) 151-4 (2000).					
	AL	Intrathecal cyclooxygenase inhibitor administration attenuates morphine antinociceptive tolerance in rats, C.S. Wong et al., <i>British Journal of Anaesthesia</i> 85 (5) 747-51 (2000).					
	AM	Cyclooxygenase inhibitors increase morphine effects on mesolimbic dopamine neurons, M. Melis, et al. <i>Eur. J. Pharmacology</i> 387 (1) R1-R3 (2000).					
	AN	Synergistic antiallodynic effects of spinal morphine with ketorolac and selective COX1- and COX2-inhibitors in nerve-injured rats, J.M. Lashbrook, et al. <i>Pain</i> 82 (1) 65-72 (1999).					
	AO	Enhancement of opioid inhibition of gaba-ergic synaptic transmission by cyclo-oxygenase inhibitors in rat penaqueductal grey neurones, Vaughn et al. <i>British Journal of Pharmacology</i> 123 (8) 1479-81 (1998).					
	AP						
	AQ						
EXAMINER				DATE CONSIDERED			
				6/29/04			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079US		SERIAL NO.: 09/154,84 10/033,057	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Ronald M. BURCH, et al.		 10/033055 12/27/01	
				FILING DATE: September 17, 1998			
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	AA	3 8 0 0 0 4 1	03/26/74	Miller, et al.	424	273	03/02/71
	AB	4 3 2 2 4 2 7	03/30/82	Buyinski, et al.	424	260	04/16/81
	AC	4 3 3 8 3 2 4	06/06/82	Gardockl	424	266	03/17/81
	AD	4 4 0 4 2 1 0	09/13/83	Schmidt	424	260	06/30/82
	AE	4 4 0 7 8 0 4	10/04/83	Schmidt	424	260	06/30/82
	AF	4 4 0 7 8 0 5	10/04/83	Schmidt	424	260	06/30/82
	AG	4 4 6 4 3 7 6	08/07/84	Sunshine, et al.	424	253	10/11/83
	AH	4 4 8 6 4 3 6	12/04/84	Sunshine, et al.	424	253	03/11/83
	AI	4 4 8 9 0 8 0	12/18/84	Lomen	424	260	12/06/82
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	AJ	2 0 2 3 3 4 9	02/18/91	Canada	A81K	31/44	
	AK	0 2 7 4 8 4 5	07/20/88	EP (A1)	A81K	31/19	
	AL	0 3 8 8 1 2 5	09/19/90	EP (A1)	A81K	31/485	
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AM	Pharmacokinetics and Drug Input Characteristics for a Diclofenac-Codeine Phosphate Combination Following Oral and Rectal Administration A. Hansen, et al. <i>Arzneim.-Forsch./Drug Res.</i> 46 (I), 57-63 (1996).					
	AN	Comparison of a Standard Ibuprofen Treatment Regimen with a New Ibuprofen/Paracetamol/Codeine Combination in Chronic Osteo-arthritis G. K. Vlok, et al. <i>Univ. Stellenbosch and Tygerberg Hospital, Dept. Orthopaedic Surg.</i> pp 3-6, (1987).					
	AO						
	AP						
	AQ						
EXAMINER 				DATE CONSIDERED 6/29/04			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079US		SERIAL NO.: 09/134,334 10/033,055	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Ronald M. BURCH, et al.			
				FILING DATE: September 17, 1998		GROUP: 1614 1639	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
MA	BA	4 5 6 7 1 8 3	01/28/86	Sunshine, et al.	514	264	12/12/83
	BB	4 5 6 9 9 3 7	02/11/86	Baker, et al.	514	282	02/11/83
	BC	4 5 7 1 4 0 0	02/18/86	Arnold	514	282	12/18/84
	BD	4 5 8 7 2 5 2	05/06/86	Arnold	514	282	12/18/84
	BE	4 6 1 9 9 3 4	12/28/86	Sunshine, et al.	514	277	07/08/85
	BF	4 6 9 0 9 2 7	09/01/87	Voss, et al.	514	282	02/03/86
	BG	4 8 3 9 1 7 6	06/13/89	Pahkhanian, et al.	424	465	12/08/87
	BH	4 8 4 4 9 0 7	07/04/89	Elger, et al.	424	465	08/14/86
	BI	4 9 2 7 8 5 4	05/22/90	Sunshine, et al.	514	570	08/21/89
	BJ	5 1 6 4 3 9 8	12/17/92	Sims, et al.	514	282	04/01/91
MA	BK	5 1 9 0 9 4 7	03/02/93	Riess, et al.	514	282	08/16/91
	BL	5 2 4 0 6 9 4	08/31/93	Gwaltney, Jr.	424	45	12/19/91
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
MA	BM	0 0 6 8 8 3 8	06/25/82	EP (A1)	A61K	31/485	Z
	BN	0 0 6 8 8 3 8	06/25/82	EP (B1)	A61K	31/485	Z
	BO	2 0 8 1 6 0 4	05/01/95	Canada	A61K	031/135	
	BP						
	BQ						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	BR						
	BS						
	BT						
EXAMINER <i>M. M.</i>				DATE CONSIDERED 01/29/04			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.1079USSERIAL NO.: 09/154,334
10/033055

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Ronald M. BURCH, et al.

FILING DATE:
September 17, 1998GROUP: 1014
1639

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>MA</i>	AA	5	4	0	9	9	4	4		04/25/95	Black, et al.	514	359	03/12/93
	AB	5	4	3	6	2	6	5		06/25/95	Black, et al.	514	420	11/12/93
	AC	5	5	1	0	3	6	8		04/23/96	Lau, et al.	514	419	05/22/95
	AD	5	5	2	1	2	1	3		05/28/96	Prasit, et al.	514	443	08/29/94
	AE	5	5	5	0	1	4	2		08/27/96	Ducharme et al.	514	365	05/08/95
	AF	5	5	5	2	4	2	2		09/03/96	Gauthier, et al.	514	368	01/11/95
	AG	5	6	0	4	2	5	3		02/18/97	Lau, et al.	514	415	05/22/95
<i>MA</i>	AH	5	6	3	9	7	8	0		06/17/97	Lau, et al.	514	419	05/22/95
	AI													

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
														YES	NO
	AJ														
	AK														
	AL														

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>MA</i>	AM	Anti-inflammatory Drugs and Their Mechanism of Action J.R. Vane, et al. Inflamm. Res. 47, Supplement 2 (1998).
	AN	
	AO	
	AP	
	AQ	

EXAMINER

McM

DATE CONSIDERED


6/29/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.1079US

SERIAL NO.: 09454334

10/033,055



LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Ronald M. BURCH, et al.

FILING DATE:
September 17, 1998GROUP: 1627
1639

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLAS S	TRANSLATION	
													YES	NO
AA	0	6	5	4	2	6	3	05/24/95	EP (A1)	A61K	31/135			
	AB	0	6	5	4	2	6	3	05/24/95	EP (B1)	A61K	31/135		
	AC	9	7	1	7	9	7	8	05/22/97	WO	A61K	33/00		
AD	9	7	2	5	9	8	8	07/24/97	WO	A61K	31/495			
	AE	9	7	3	2	8	5	7	09/12/97	WO	C07D	241/104		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AF	Dray et al. New Pharmacological Strategies for Pain Relief. <u>Annual Review of Pharmacology & Toxicology</u> , 36, pp. 253-280. (1996).
AG	Brasseur, L. Revue des therapeutiques pharmacologiques actuelles de la douleur. <u>Drugs</u> , 53 Suppl 2, pp. 10-17. (1997)
AH	Rang et al. New molecules in analgesia. <u>British Journal of Anesthesia</u> , 75, pp. 145-156 (1995)
AI	Beaver, WT. Combination Analgesics. <u>American Journal of Medicine</u> , 77 (Suppl 3A), pp. 38-53. (1984).
AJ	Beaver, WT. Chapter 29: Nonsteroidal Antiinflammatory Analgesics and Their Combinations with Opioids. In <u>Evaluation and Treatment of Chronic Pain</u> , 2 nd ed., William & Wilkins pp. 363-383. (1992).
AK	Goodman & Gilman's. <u>The Pharmacological Basis of Therapeutics</u> , 9 th Edition. McGraw-Hill, New York, pp 535 and 551-552.
AL	Picard et al. Ketorolac potentiates morphine in postoperative patient-controlled analgesia. <u>Pain</u> , 73, 3 pp. 401-406. (1997).
AM	Elches et al. Continuous Intravenous Administration of Ketorolac Reduces Pain and Morphine Consumption After Total Hip or Knee Arthroplasty. <u>Anesthesia & Analgesia</u> , 81 (6), pp. 1175-1180. (1995).
AN	Hodsman et al. The morphine sparing effects of diclofenac sodium following abdominal surgery. <u>Anaesthesia</u> , 42(9), pp. 1005-1008. (1987).
AO	Kaasalainen et al. Developments in the treatment of cancer pain in Finland: The third nation-wide survey. <u>Pain</u> , 70, 2-3, pp. 175-183. (1997).
AP	Sunshine et al. Analgesic Efficacy of a Hydrocodone with Ibuprofen Combination Compared with Ibuprofen Alone for the Treatment of Acute Postoperative Pain. <u>Journal of Clinical Pharmacology</u> , 37 (10), pp. 908-915. (1997).
AQ	Insel. Chapter 27: Analgesic-Antipyretic and Anti-Inflammatory Agents. In Hardman, ed., <u>Goodman & Gilman's The Pharmacological Basis of Therapeutics</u> , 9 th Edition. McGraw-Hill, New York, pp. 654-655. (1996).
AR	Polisson. Non-steroidal Anti-Inflammatory Drugs: Practical and Theoretical Consideration in Their Selection. <u>The American Journal of Medicine</u> , 100 (Suppl 2A), pp. 2A-31S - 2A-36S. (1996).
AS	Vane, J. Towards a better aspirin. <u>Nature</u> , 367, pp. 215-216. (1994).
AT	Simon, L.S. Nonsteroidal Antiinflammatory Drugs and Their Effects: The Importance of COX 'Selectivity'. <u>Journal of Clinical Rheumatology</u> , 2 (3), pp. 135-140. (1996).

EXAMINER


DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

DEC 02 2002

TECH CENTER 1600/2900



FORM PTO 49 (REV. 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: 200.1079US	SERIAL NO.: 09/154,354 101 033,055
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT(S): Ronald M. BURCH, et al.	
		FILING DATE: September 17, 1998	GROUP: 1627 1639
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)			
BA	Van Ryn et al. Selective cyclooxygenase-2 inhibitors: pharmacology, clinical effects, and therapeutic potential. <u>Expert Opinion On Investigational Drugs</u> , pp. 609-614. (1997).		
BB	Vane et al. New insights into the mode of action of anti-inflammatory drugs. <u>Inflammation Research</u> , 44, (No.1), pp 1-10 (1995).		
BC	Engelhardt. Meloxicam: A Preferential Inhibitor of COX-2. <u>British Journal of Rheumatology</u> , 34, Abstract Suppl. 1, p. 48. (1995). Abstract.		
BD	Lane, N.E. Pain Management in Osteoarthritis: The Role of COX-2 Inhibitors. <u>Journal of Rheumatology</u> , Vol. 24, Suppl 49, pp. 20-24. (1997).		
BE	Boyce et al. L-745,337: A Selective Inhibitor of Cyclooxygenase-2 Elicits Antinociception But Not Gastric Ulceration in Rats. <u>Neuropharmacology</u> Vol. 33, pp. 1609-1611. (1994).		
BF	Donnelly et al. COX-II Inhibitors - a new generation of safer NSAIDS? <u>Alimentary Pharmacology and Therapeutics</u> , 11, 2, pp. 227-236. (1997).		
BG	Wallace, J.L. Nonsteroidal Anti-inflammatory Drugs and Gastroenteropathy: The Second Hundred Years. <u>Gastroenterology</u> , 112, 3, pp. 1000-1016. (1997).		
BH	Robinson, D.R. Regulation of Prostaglandin Synthesis by Antiinflammatory Drugs. <u>J Rheumatology</u> , 24, Suppl. 47, pp. 32-39. (1997).		
BI	Tannenbaum et al. An Evidence-Based Approach to Prescribing NSAIDS in Musculoskeletal Disease: A Canadian Consensus. <u>Canadian Medical Association Journal</u> , 155, 1, pp. 77-88. (1996).		
BJ	Mehlich et al. Analgesic Efficacy and Plasma Levels of a Highly Selective Inhibitor of COX-2 (SC-58635, SC) in Patients with Postsurgical Dental Pain. <u>Journal of Clinical Pharmacology</u> , 37, 9, 883. (1997). Abstract.		
BK	Dammann. Selective COX-2 Inhibition: Its Relevance for NSAID-Gastrointestinal Toxicity. <u>Gut</u> , 39, Suppl. 3, A151. (1996). Abstract.		
BL	Penning et al. Synthesis and Biological Evaluation of the 1, 5 -diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib). <u>Journal Of Medicinal Chemistry</u> , 40(9), 1347-65. (1997).		
BM	Lipsky et al. Outcome of Specific COX-2 Inhibition in Rheumatoid Arthritis. <u>Journal Of Rheumatology</u> , 24 Suppl 49, pp. 9-14. (1997).		
BN			
BO			
BP			
BQ			
BR			
BS			
BT			
EXAMINER	DATE CONSIDERED 6/29/04		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

RECEIVED
DEC 02 2002
TECH CENTER 1600/2900



Sheet 1 of 1

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.1079US

SERIAL NO.:

09/154,354 10/033,055

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Ronald M. BURCH, et al.

FILING DATE:
September 17, 1998GROUP:
1627 1639

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
AM	0 7 3 4 2 7 5	11/04/1997	Australia	C07D	261/08		
AH							
AI							
AJ							
AK							
AL							

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AM	
AN	
AO	
AP	
AQ	
AR	
AS	

EXAMINER

DATE CONSIDERED

RECEIVED
DEC 8 2 2002
TECH CENTER 1800/2800

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.